Eligible participants for this study must have a diagnosis of Neurodegenerative Disorder and must exhibit disinhibition syndrome of sufficient severity to warrant treatment.~This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study consisting of two 6-week treatment periods.~Approximately 12 participants will be enrolled at approximately 2 centers in the United States.~Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants will be randomized into the study.
Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.